News Center
Support for Epidemic Prevention - Lijun Group's COVID-19 Antigen Test Kit Approved for Market Launch
Release time:
2022-04-14
On April 13, good news came from the National Medical Products Administration that the new coronavirus (2019-nCoV) antigen detection kit (latex method) independently developed by Lizhu Group's subsidiary, Lizhu Reagent Co., Ltd., has been approved for marketing, registration certificate number: National Medical Device Approval 20223400470. The approval of this product can effectively alleviate the domestic testing pressure and assist in epidemic prevention and control.
On March 11, the State Council issued a notice on the "Application Plan for COVID-19 Antigen Testing (Trial)" deciding to add antigen testing as a supplement to nucleic acid testing. Lizhu Reagent immediately initiated the registration process. Prior to this, Lizhu Reagent's COVID-19 antigen reagent had obtained registration certificates from the EU CE, the UK, Indonesia, and Thailand, as well as whitelist access qualifications from countries and regions such as France, Germany, and Austria, with products sold to multiple countries and regions in the EU and Asia-Pacific.
The Lizhu Reagent new coronavirus (2019-nCoV) antigen detection kit (latex method) is used for the in vitro qualitative detection of the new coronavirus (2019-nCoV) N protein antigen in human nasopharyngeal swabs, oropharyngeal swabs, and nasal swab samples. It is suitable for medical and health institutions at all levels, quarantine observers, and community residents with self-testing needs. It does not rely on testing equipment and can obtain test results within 15 to 20 minutes, with advantages such as rapid testing, accurate results, easy operation, and user-friendly design. Compared to publicly available data of similar products already on the market, Lizhu Reagent's COVID-19 antigen reagent has a higher compliance rate with nucleic acid testing.
Since the outbreak of the COVID-19 pandemic, Lizhu Group has actively participated in epidemic prevention and control, leveraging its advantages in research and development innovation, and quickly developed the new coronavirus IgM/IgG antibody detection kit (colloidal gold method), which has been approved for marketing. The successful approval of the new coronavirus (2019-nCoV) antigen detection kit (latex method) adds a new member to Lizhu Group's "epidemic fighting" product line.
Additionally, it is reported that the ceremony for donating epidemic prevention materials from Zhuhai City to Yunfu City was held on April 13 in Luoding City, Yunan County, and Yunfu City. Upon learning that Lizhu Group's COVID-19 antigen detection kit was approved for marketing, leaders from Zhuhai and Yunfu cities expressed their congratulations. The Zhuhai municipal government made its first purchase of 110,000 COVID-19 antigen detection kits to donate to Yunfu City, Luoding City, and Yunan County for epidemic prevention. Zhuhai Mayor Huang Zhihao led the team, and Vice Mayor Hu Xintian represented the Zhuhai municipal government for the donation. At the same time, Group Vice President Zhou Peng represented Lizhu Group to donate a total of 72,000 boxes of antiviral granules to Yunfu City, Luoding City, and Yunan County, contributing Lizhu's strength to epidemic prevention and control.
Related Information